BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33864178)

  • 1. Augmentation in patients with restless legs syndrome receiving pramipexole therapy: a retrospective study in a single center from China.
    Wang T; Ying M; Zhao R; Zhu D; Zhang L
    Sleep Breath; 2022 Mar; 26(1):373-380. PubMed ID: 33864178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).
    Winkelman JW; Johnston L
    Sleep Med; 2004 Jan; 5(1):9-14. PubMed ID: 14725821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study.
    Takahashi M; Nishida S; Nakamura M; Kobayashi M; Matsui K; Ito E; Usui A; Inoue Y
    PLoS One; 2017; 12(3):e0173535. PubMed ID: 28264052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole in the management of restless legs syndrome: an extended study.
    Silber MH; Girish M; Izurieta R
    Sleep; 2003 Nov; 26(7):819-21. PubMed ID: 14655914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pregabalin with pramipexole for restless legs syndrome.
    Allen RP; Chen C; Garcia-Borreguero D; Polo O; DuBrava S; Miceli J; Knapp L; Winkelman JW
    N Engl J Med; 2014 Feb; 370(7):621-31. PubMed ID: 24521108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
    Winkelman JW
    Sleep; 2022 Feb; 45(2):. PubMed ID: 34417810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
    Bayard S; Langenier MC; Dauvilliers Y
    Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of pramipexole in the management of restless legs syndrome.
    Lipford MC; Silber MH
    Sleep Med; 2012 Dec; 13(10):1280-5. PubMed ID: 23036265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation in restless legs syndrome patients in Korea.
    Jeon JY; Moon HJ; Song ML; Lee HB; Cho YW
    Sleep Breath; 2015 May; 19(2):523-9. PubMed ID: 25082663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole in the treatment of restless legs syndrome: a follow-up study.
    Montplaisir J; Denesle R; Petit D
    Eur J Neurol; 2000 May; 7 Suppl 1():27-31. PubMed ID: 11054156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restless legs syndrome: differential diagnosis and management with pramipexole.
    Brindani F; Vitetta F; Gemignani F
    Clin Interv Aging; 2009; 4():305-13. PubMed ID: 19750232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system?
    Rocchi C; Albanese M; Placidi F; Romigi A; Lauretti B; Marfia GA; Liguori C; Marciani MG; Mercuri NB; Izzi F
    Sleep Med; 2015 Sep; 16(9):1071-6. PubMed ID: 26298781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
    Maestri M; Fulda S; Ferini-Strambi L; Zucconi M; Marelli S; Staedler C; Bassetti CL; Manconi M
    Sleep Med; 2014 May; 15(5):570-5. PubMed ID: 24767724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
    Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
    J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndrome patients with low serum ferritin.
    Lee CS; Lee SD; Kang SH; Park HY; Yoon IY
    Eur J Neurol; 2014 Feb; 21(2):260-6. PubMed ID: 24267148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
    Garcia-Borreguero D; Kohnen R; Silber MH; Winkelman JW; Earley CJ; Högl B; Manconi M; Montplaisir J; Inoue Y; Allen RP
    Sleep Med; 2013 Jul; 14(7):675-84. PubMed ID: 23859128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.